Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Gilead re­ports 'very strong quar­ter' de­spite slip­ping Vek­lury sales

Gilead CEO Dan O’Day un­corked some sol­id Q2 re­sults on Tues­day, tout­ing a surge in Yescar­ta and Trodelvy sales and an uptick in de­mand for HIV med Bik­tarvy. Will sink­ing Covid sales spoil the par­ty?

Vek­lury sales were down 48% last quar­ter, top­ping out at $445 mil­lion. That de­cline was ex­pect­ed, chief com­mer­cial of­fi­cer Jo­han­na Merci­er not­ed, as hos­pi­tal­iza­tion rates fall due to milder cas­es and the up­take of oth­er treat­ments like Pfiz­er’s Paxlovid. Even so, rough­ly 60% of hos­pi­tal­ized Covid pa­tients are treat­ed with Vek­lury, she added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.